SEC Filings

AVEXIS, INC. filed this Form 8-K on 01/04/2018
Entire Document


Item 8.01.             Other Events.


On January 4, 2018, AveXis, Inc. (the “Registrant”) issued a press release to provide an update following the receipt of minutes from the Registrant’s end-of-Phase 1 meeting with the U.S. Food and Drug Administration conducted on December 5, 2017, regarding the Registrant’s primary gene therapy candidate, AVXS-101, for the treatment of spinal muscular atrophy Type 1.  A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01.             Financial Statements and Exhibits.


(d) Exhibits




Exhibit Description



Press Release, dated January 4, 2018, titled “AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1.”



© AveXis, Inc. All Rights Reserved.